Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Description:
Host: Vera Bril, MD
Guest: Neelam Goyal, MD
Traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial for many patients in the short term but often come with unacceptable side effects. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) has created a groundbreaking paradigm shift in our approach to both the short- and longer-term management of affected patients. Join Drs. Vera Bril and Neelam Goyal as they take a deep dive into this topic and discuss how FcRn inhibitors are changing the therapeutic landscape of gMG.